Hépato-Gastro & Oncologie Digestive


Immunotherapy: Therapeutic perspectives in hepatocellular carcinoma and management of gastrointestinal side effects Volume 23, issue 6, Juin 2016


  • Figure 1

  • Figure 2


CHU de Vandoeuvre-lès-Nancy,
service d’hépato-gastro-entérologie,
5, rue du Morvan,
54510 Vandoeuvre-lès-Nancy,
France ;
Université de Lorraine,
* Tirés à part

The immune system is involved in the prevention and control of tumors, this phenomenon is called the cancer immunosurveillance. The hepatic immune tolerance is an obstacle to obtain an effective response to tumor antigen response of hepatocellular carcinoma (HCC). The goal of immunotherapy in HCC is to guide and mobilizes the anti-tumor immune response using three different strategies : adoptive immunotherapy, therapeutic vaccination and blocking immune checkpoints. The latter strategy uses the blocking receptors on T cells, which, combined with their ligands, cause a cascade of signal activation and lymphocyte proliferation. The anti-CTLA-4 monoclonal antibodies and anti-PD1 inhibitors are the two main treatments for immune control check points in clinical development. The main adverse events are immunological and include gastrointestinal and hepatic injuries.